Lonafarnid has shown clear benefits in the treatment of HGPS, yet its use is associated with side effects linked to inflammatory pathways and cell death mediated by the NLRP3 inflammasome, a process known as pyroptosis (Coss, 2020). The gene discussed is NLRP3; the disease is Hutchinson-Gilford progeria syndrome.